Figure 4. Kaplan Meier survival analysis for combined LC3B dot like/p62 dot like-cytoplasmic staining for subgroups.

(A) Tumors with adjuvant treatment (B) non-metastasized tumors (i.e. UICC/AJCC stages I-II) (C) left sided carcinomas (D) MMR proficient carcinomas